InMed Pharmaceuticals Inc

詳細情報 InMed Pharmaceuticals Inc 企業名

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

企業情報

企業コードINM

会社名InMed Pharmaceuticals Inc

上場日Jun 21, 2001

最高経営責任者「CEO」Mr. Eric A. Adams

従業員数- -

証券種類Ordinary Share

決算期末Jun 21

本社所在地1445-885 West Georgia St.

都市VANCOUVER

証券取引所NASDAQ Capital Market Consolidated

国Canada

郵便番号V6C 3E8

電話番号16046697207

ウェブサイトhttps://www.inmedpharma.com/

企業コードINM

上場日Jun 21, 2001

最高経営責任者「CEO」Mr. Eric A. Adams

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Andrew Harold Hull

Independent Chairman of the Board

1.91K

-18.19%

Dr. Eric Chih-Hsien Hsu, Ph.D.

Senior Vice President - Preclinical Research and Development

2.00

-99.90%

Mr. Michael Henry Woudenberg

Chief Operating Officer

1.00

-99.96%

Mr. Bryan T. Baldasare

Independent Director

--

Ms. Nicole Lemerond

Independent Director

--

-100.00%

Mr. Eric A. Adams

President, Chief Executive Officer, Director

--

Ms. N. Netta (Neeta) Jagpal, CPA

Chief Financial Officer, Corporate Secretary

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Andrew Harold Hull

Independent Chairman of the Board

1.91K

-18.19%

Dr. Eric Chih-Hsien Hsu, Ph.D.

Senior Vice President - Preclinical Research and Development

2.00

-99.90%

Mr. Michael Henry Woudenberg

Chief Operating Officer

1.00

-99.96%

Mr. Bryan T. Baldasare

Independent Director

--

Ms. Nicole Lemerond

Independent Director

--

-100.00%

Mr. Eric A. Adams

President, Chief Executive Officer, Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Fri, Jul 11

株主統計

種類

株主統計

比率

Yorkville Advisors Global, LP.

6.66%

Sabby Management, LLC

2.99%

UBS Financial Services, Inc.

0.51%

Adams (Eric Ashley)

0.18%

Hull (Andrew Harold)

0.16%

Other

89.50%

株主統計

比率

Yorkville Advisors Global, LP.

6.66%

Sabby Management, LLC

2.99%

UBS Financial Services, Inc.

0.51%

Adams (Eric Ashley)

0.18%

Hull (Andrew Harold)

0.16%

Other

89.50%

種類

株主統計

比率

Investment Advisor/Hedge Fund

9.65%

Individual Investor

0.98%

Investment Advisor

0.51%

Research Firm

0.03%

Other

88.84%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

37

127.03K

10.52%

+19.01K

2025Q1

34

127.03K

10.75%

+32.44K

2024Q4

33

169.52K

14.04%

+76.54K

2024Q3

35

65.17K

63.92%

+11.73K

2024Q2

34

30.10K

7.60%

-6.51K

2024Q1

33

42.40K

13.49%

-1.13K

2023Q4

31

40.41K

15.37%

-91.29K

2023Q3

32

1.59K

1.33%

-12.58K

2023Q2

37

1.04K

0.99%

-13.60K

2023Q1

44

5.33K

3.61%

-4.80K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Yorkville Advisors Global, LP.

80.37K

6.66%

+80.37K

--

Dec 13, 2024

Sabby Management, LLC

36.13K

2.99%

+20.77K

+135.22%

Dec 31, 2024

UBS Financial Services, Inc.

6.11K

0.51%

-4.30K

-41.33%

Mar 31, 2025

Adams (Eric Ashley)

7.89K

0.65%

+5.70K

+259.26%

May 11, 2025

Hull (Andrew Harold)

2.34K

0.19%

+425.00

+22.23%

May 11, 2025

SBI Securities Co., Ltd.

300.00

0.02%

+300.00

--

Mar 31, 2025

Banque Cantonale Vaudoise

6.00

0%

--

Mar 31, 2025

Hsu (Eric Chih-Hsien)

1.95K

0.16%

+1.95K

+97300.00%

May 11, 2025

AllSquare Wealth Management LLC

1.00

0%

--

Mar 31, 2025

Desjardins Securities Inc.

1.00

0%

--

Mar 31, 2025

詳細を見る

2.375USD

InMed Pharmaceuticals Inc

2.375

概要

企業名

金融